title: Identification of novel molecular targets for endometrial cancer using a drill-down LC-MS/MS approach with iTRAQ.
abstract: BACKGROUND
  The number of patients with endometrial carcinoma (EmCa) with advanced stage or high histological grade is increasing and prognosis has not improved for over the last decade. There is an urgent need for the discovery of novel molecular targets for diagnosis, prognosis and treatment of EmCa, which will have the potential to improve the clinical strategy and outcome of this disease.
  
  
  RESULTS
  We used a "drill-down" proteomics approach to facilitate the identification of novel molecular targets for diagnosis, prognosis and/or therapeutic intervention for EmCa. Based on peptide ions identified and their retention times in the first LC-MS/MS analysis, an exclusion list was generated for subsequent iterations. A total of 1529 proteins have been identified below the Proteinpilot® 5% error threshold from the seven sets of iTRAQ experiments performed. On average, the second iteration added 78% new peptides to those identified after the first run, while the third iteration added 36% additional peptides. Of the 1529 proteins identified, only 40 satisfied our criteria for significant differential expression in EmCa in comparison to normal proliferative tissues. These proteins included metabolic enzymes (pyruvate kinase M2 and lactate dehydrogenase A); calcium binding proteins (S100A6, calcyphosine and calumenin), and proteins involved in regulating inflammation, proliferation and invasion (annexin A1, interleukin enhancer-binding factor 3, alpha-1-antitrypsin, macrophage capping protein and cathepsin B). Network analyses revealed regulation of these molecular targets by c-myc, Her2/neu and TNF alpha, suggesting intervention with these pathways may be a promising strategy for the development of novel molecular targeted therapies for EmCa.
  
  
  CONCLUSIONS
  Our analyses revealed the significance of drill-down proteomics approach in combination with iTRAQ to overcome some of the limitations of current proteomics strategies. This study led to the identification of a number of novel molecular targets having therapeutic potential for targeted molecular therapies for endometrial carcinoma.
authors.affiliation: Department of Chemistry and Centre for Research in Mass Spectrometry, York University, Toronto, Ontario, Canada.
authors.forename: Sébastien N
authors.initials: SN
authors.lastname: Voisin
authors.forename: Olga
authors.initials: O
authors.lastname: Krakovska
authors.forename: Ajay
authors.initials: A
authors.lastname: Matta
authors.forename: Leroi V
authors.initials: LV
authors.lastname: DeSouza
authors.forename: Alexander D
authors.initials: AD
authors.lastname: Romaschin
authors.forename: Terence J
authors.initials: TJ
authors.lastname: Colgan
authors.forename: K W Michael
authors.initials: KW
authors.lastname: Siu
mesh_terms: D002853:Chromatography, Liquid; D016889:Endometrial Neoplasms / Q000737:chemistry* / Q000175:diagnosis / Q000188:drug therapy; D005260:Female; D006801:Humans; D058990:Molecular Targeted Therapy / Q000379:methods*; D009363:Neoplasm Proteins / Q000032:analysis*; D011379:Prognosis; D040901:Proteomics / Q000379:methods*; D053719:Tandem Mass Spectrometry
chemical_list: D009363:Neoplasm Proteins